,
3. Key preparation activities are now underway to advance clinical programs in these high priority target indications including (but not limited to): trial design, regulatory consultation, endpoint selection, key opinion leader engagements and clinical site selection. The Company will continue to develop its existing clinical product pipeline in addition to these new targets and will continue to drive its partnering strategy. Further background information on the new target indications is provided below.
Idiopathic Pulmonary Fibrosis (IPF)
IPF is an incurable disease of unknown cause, which results in extensive scarring (or fibrosis) of the lungs. When first diagnosed, lung damage is often advanced and invariably progresses to respiratory failure with only 20% to 30% of patients surviving five years after diagnosis
Published: Dec 11, 2020
Immunology Drug Market: Snapshot
The rising threat of immunological and autoimmune diseases across the globe and the escalating awareness about ways to overcome these diseases may help the immunology drug market may gain substantial growth across the assessment period of 2020-2030.
The immune system is one of the most important components of the human body. It protects and guards the body against diseases and foreign bodies. It detects threats like viruses, parasites, and bacteria. When the immune system is weak or becomes incapable of protecting the body from diseases or disorders, it leads to autoimmune diseases and cancer.
Rising incidences of pre-eclampsia globally
The incidence of pre-eclampsia, a precursor to eclampsia, varies greatly worldwide. WHO estimates the incidence of preeclampsia to be seven times higher in developing countries (2.8% of live births) than in developed countries (0.4%). According to American Heart Association, Inc., the greatest morbidity and mortality, preeclampsia affects 5% to 7% of all pregnant women; however, it is responsible for over 70 000 maternal deaths and 500 000 fetal deaths worldwide every year.
According to Swiss Medical Weekly, risks for developing pre-eclampsia include nulliparity, prior pre-eclampsia, pre-existing hypertension, renal disease, gestational or pre-existing diabetes mellitus, and a family history of pre-eclampsia, maternal age of ≥35 years, multiple gestation, obesity, and a long interpregnancy interval.
Published: Dec 11, 2020
Rare Disease Gene Therapy Market: Snapshot
The global rare disease gene therapy is expected to witness a significant growth in the forecast period, 2020-2030 on account of the increasing cases of genetic diseases worldwide. Gene therapy is relevant to rare disease patients and has improved the wellbeing and personal satisfaction of more seasoned kids and youthful grown-ups with X-SCID. These kids are expected to experience complex clinical issues in the wake of getting live-sparing bone marrow transfers to treat the condition.
The report offers insights into the market emphasizing on factors boosting, repelling, challenging, and creating opportunities for the market in the forecast period. It also discusses the impact of the COVID-19 pandemic on the overall market. It also discusses the table of segmentation in details and lists the names of the prominent players functioning in the market.